Clinical Trial Update: Enhancing Weight Loss Maintenance With GLP-1RA (BYDUREON™) in Adolescents With Severe Obesity [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating BYDUREON™ (GLP-1 receptor agonist) for weight loss maintenance in adolescents with severe obesity; study completed with posted results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• Bydureon (exenatide)

Snippet

Sponsor: University of Minnesota | Conditions: Severe Obesity | Phase 2 | Status: COMPLETED | Results posted: 2022-01-03